Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S, dated June 15, 2026, reports on the company's ongoing share repurchase programme. Novo Nordisk is a global healthcare company headquartered in Denmark, employing approximately 68,800 people across 80 countries. The filing details transactions executed under a programme initiated on May 6, 2026, which is part of a broader authorization to repurchase up to DKK 15 billion in shares over a 12-month period starting February 4, 2026.
Key Financial Metrics
The filing focuses on capital allocation activities rather than operational financial performance. Key metrics include:
- Share Repurchase Programme Cap: DKK 15 billion (total programme from Feb 4, 2026).
- Specific Tranche Cap: DKK 11,200,000,010.45 (May 6, 2026 to Feb 1, 2027).
- Total Repurchased (since Feb 4, 2026): 19,884,179 B shares.
- Average Purchase Price (since Feb 4, 2026): DKK 264.99 per B share.
- Total Transaction Value (since Feb 4, 2026): DKK 5,269,055,819.
- Treasury Shares Held: 37,069,480 B shares (0.8% of share capital).
- Total Share Capital: 4,465,000,000 A and B shares (including treasury shares).
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
Since the last announcement on June 8, 2026, the company executed five additional repurchase transactions between June 9 and June 12, 2026. These transactions involved 1,125,000 B shares at an aggregate value of approximately DKK 310.6 million. The average purchase price for these specific recent transactions ranged from DKK 268.40 to DKK 283.72.
Guidance, Outlook, and Risks
Management expects to continue repurchasing B shares up to the DKK 15 billion limit during the 12-month period beginning February 4, 2026. The programme is conducted in accordance with EU Market Abuse Regulation (MAR) and Safe Harbour Rules. The filing does not contain specific operational guidance, risk factors, or contingencies beyond the standard regulatory compliance for share buybacks.
Investor Verification Checklist
- Verify the remaining capacity under the DKK 15 billion total repurchase authorization.
- Confirm the current market price of Novo Nordisk B shares relative to the recent average purchase price of DKK 264.99.
- Review the full transaction history on novonordisk.com for details beyond the summary provided.
- Check the impact of the 0.8% treasury share holding on earnings per share (EPS) calculations in upcoming financial reports.